Mavacamten Reduces LVOT Obstruction Risk, Enabling Transseptal Mitral Valve-in-Valve for Degenerated Bioprosthesis. [PDF]
JACC Case RepHoss A, Voß F, Polzin A.
europepmc +1 more source
The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive). [PDF]
Eur Heart J SupplBiagini E, Schiavo MA.
europepmc +1 more source
Effect of Mavacamten Therapy on Myocardial Systolic Function Assessed by 3D Echocardiography. [PDF]
JACC Case RepPolizzi R +5 more
europepmc +1 more source
Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors. [PDF]
ESC Heart FailErzeel J +6 more
europepmc +1 more source
One- and two-year structural changes of mavacamten therapy in hypertrophic obstructive cardiomyopathy: a case report with serial comprehensive CMR demonstrating continuous reverse remodelling. [PDF]
Eur Heart J Case RepSeuthe K +4 more
europepmc +1 more source
Still at sea: a patient's ongoing journey with non-obstructive hypertrophic cardiomyopathy. [PDF]
Eur Heart J Case RepGoldie FC, Myles RC, Coats CJ.
europepmc +1 more source
Paradoxical Pulmonary Congestion After Mavacamten in Obstructive HCM: A Case Illustrating Hemodynamic Transition. [PDF]
JACC Case RepTabata N +5 more
europepmc +1 more source
Mavacamten optimizes myocardial work in patients with obstructive hypertrophic cardiomyopathy: a non-invasive pressure-strain analysis. [PDF]
Clin Res CardiolScholtz S +9 more
europepmc +1 more source
Mavacamten in Symptomatic Hypertrophic Cardiomyopathy
JACC: AsiaChung-Lieh Hung, Yen-Wen Liu, Yen-Wen Wu
openaire +1 more source